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continuous renal replacement in critically ill patients.
Background. We determined the effect of regional citrate
versus systemic heparin anticoagulation for continuous renal re-
placement therapy in critically ill subjects suffering from acute
renal failure who were not at high risk for hemorrhagic compli-
cations.
Methods. Between April 1999 and June 2002, 30 critically
ill subjects requiring continuous renal replacement therapy and
using 79 hemofilters were randomly assigned to receive regional
citrate or systemic heparin anticoagulation.
Results. The median hemofilter survival time was 124.5 hours
(95% CI 95.3 to 157.4) in the citrate group, which was signifi-
cantly longer than the 38.3 hours (95% CI 24.8 to 61.9) in the
heparin group (P < 0.001). Increasing illness severity score,
male gender, and decreasing antithrombin-III levels were inde-
pendent predictors of an increased relative hazard of hemofil-
ter failure. After adjustment for illness severity, antithrombin-
III levels increased significantly more over the period of study
in the citrate as compared to the heparin group (P = 0.038).
Moreover, after adjustment for antithrombin-III levels and ill-
ness severity score, the relative risk of hemorrhage with citrate
anticoagulation was significantly lower than that with heparin
(relative risk of 0.14; 95% CI 0.02 to 0.96, P = 0.05).
Conclusion. Compared with systemic heparin anticoagu-
lation, regional citrate anticoagulation significantly increases
hemofilter survival time, and significantly decreases bleeding
risk in critically ill patients suffering from acute renal failure
and requiring continuous renal replacement therapy.
Acute renal failure (ARF) is a common complication of
critically ill patients with mortality rates in excess of 40%
[1–6]. The use of continuous renal replacement therapy
(CRRT) in the management of acute renal failure in crit-
ically ill patients has become accepted, and based on two
North American surveys, it has been estimated that one
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quarter of all patients in the United States and Canada
with acute renal failure are treated with CRRT [6–8].
The requirement for continuous systemic anticoagula-
tion is a major drawback to the use of CRRT. Systemic
anticoagulation with unfractionated heparin has been the
anticoagulant of choice, with regional citrate anticoagu-
lation being used as the method of choice in only 13% of
patients in Canada [8, 9]. The use of regional citrate an-
ticoagulation has been described in the setting of CRRT,
and one randomized trial has suggested its superiority
over that of heparin [10–12]. However, a recent confer-
ence on CRRT failed to provide a consensus on the pre-
ferred anticoagulant for most CRRT patients, offering a
recommendation to avoid systemic anticoagulation with
heparin in patients at high risk for hemorrhage [7].
We have previously described an algorithm for regional
citrate anticoagulation in CRRT [11]. The objective of
this study was to compare the hemofilter survival times
and bleeding risks in critically ill patients undergoing
CRRT for ARF. Patients were randomized to receive ei-
ther systemic unfractionated heparin or regional citrate
anticoagulation.
METHODS
Study design and population
Eligible patients were 18 years old or older and suf-
fering from ARF using a standard definition, and were
admitted to either of two tertiary care intensive care
units (ICUs) or one community hospital ICU [5]. Pa-
tients were excluded if they had a contraindication to
the use of systemic heparin or trisodium citrate or if
they were anticipated to require systemic heparin for
medical reasons. Contraindications to the use of hep-
arin included a prior history of heparin-induced throm-
bocytopenia or heparin allergy, intracranial hemorrhage
within three months, gastrointestinal hemorrhage requir-
ing a transfusion of greater than two units of blood within
three months, active bleeding within three days or signif-
icant trauma within three days, a platelet count <40,0000
per mm3, and evidence of a irreversible coagulopathy
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(INR >2.5, PTT >65, or fibrinogen <1.00 g/L) as a re-
sult of liver failure, disseminated intravascular coagula-
tion, or a coagulation factor deficiency. Contraindication
to the use of trisodium citrate included a serum ionized
calcium level of <0.70 mmol/L, a serum pH of >7.60, and
a serum sodium of >160 mmol/L. Pregnant females were
also excluded from the study. Ethics approval was ob-
tained from regional ethics boards, and written informed
consent was obtained for all subjects prior to randomiza-
tion.
Randomization and interventions
Consecutive eligible patients were randomized to an-
ticoagulation with either heparin or citrate within vari-
able block sizes of 4 and 8. Treatment assignment was
not blinded given the requirement of following levels
of PTT and INR. Subjects randomized to the heparin
group received an initial bolus of 50 U/kg of heparin for
a PTT ≤35 seconds (no heparin bolus if the PTT was
>35 seconds), followed by an algorithm titrated to main-
tain a systemic PTT between 45 and 65 seconds. Subjects
randomized to receive citrate received trisodium citrate
titrated to maintain posthemofilter ionized calcium levels
between 0.25 and 0.35 mmol/L. Details of the trisodium
citrate algorithm have been previously described [11]. In
the heparin treatment group, INR and PTT levels were
performed at least every four hours according to a stan-
dardized dosing nomogram. In the citrate group, post-
hemofilter and serum ionized and total calcium levels
were monitored one hour after initiation of regional cit-
rate anticoagulation, at four-hour intervals thereafter for
24 hours, followed by monitoring every eight hours. The
hemofilters in both treatment groups were primed with
10,000 U of heparin in 1 L of normal saline prior to the
initiation of CRRT. CRRT was performed as continuous-
veno-venous hemodiafiltration using the PRISMA CFM
system (Gambro Renal Products, Montreal, Canada)
with a standard PRISMA M-100 AN69 (polyacriloni-
trile) hemofilter. Unfractionated heparin has previously
been demonstrated to bind to both AN69 and the newer
AN69ST hemofilter membranes, and to provide an an-
ticoagulant effect with a simultaneous reduction of sys-
temic anticoagulation requirements [13]. Blood flow rates
were maintained at 125 mL/min, with dialysate flow rates
of 1000 mL/hr and hemofiltration rates (prehemofilter) of
1000 mL/hr. Fluid removal rates were left to the discre-
tion of the attending physician in order to achieve optimal
hemodynamic balance; however, these rates were not per-
mitted to exceed a net negative balance of 300 mL/hour
by protocol. The dialysis and replacement solution used
was produced either by the regional pharmacy of the par-
ticipating centers, or provided as an equivalent preformu-
lated solution (Gambro Dasco SpA, Medolla, Italy), and
consisted of Na+ 117 mmol/L, Mg++ 0.70 mmol/L, and
Cl− 117 mmol/L. The attending physician dictated the
concentration of KCl and HCO3− to be used in the dial-
ysis/replacement fluid solution. Doses of HCO3− used
in the replacement fluid of both treatment groups var-
ied between 33.3 mmol/L and 50 mmol/L, and in the pa-
tients randomized to the heparin group, HCO3− was also
permitted to be included at similar concentrations in the
dialysis solution.
The logistic organ dysfunction (LOD) score, which in-
cluded the platelet count and INR in its composite score,
was measured during the 24-hour period after ICU ad-
mission [14]. Protein C levels (using a clot-based assay
STA instrument), antithrombin III (AT-III) levels (using
a chromogenic method STA instrument), and the LOD
score were measured just prior to initiation of CRRT, day
4 and 7 after CRRT initiation, and weekly thereafter until
day 21.
Follow-up and outcome measures
All patients were followed to hospital discharge or
death. Hemofilter failure was defined as hemofilter clot-
ting or persistent transmembrane pressures greater than
200 mm Hg, resulting in repeatedly triggering the “high
pressure” alarm and subsequently prohibiting continua-
tion of CRRT at the prescribed dose. Definite bleeding
was defined when a site of gross bleeding had been wit-
nessed, and at least one of the following criteria was met:
(1) a spontaneous drop of ≥20 mm Hg in systolic or di-
astolic blood pressure within 24 hours; (2) an increase in
heart rate of 20 bpm and a drop in systolic blood pressure
of 10 mm Hg on assuming an upright position; (3) trans-
fusion of ≥2 U packed red blood cells within 24 hours;
(4) failure of the hemoglobin concentration (in g/dL) to
increase after transfusion by at least the number of units
transfused minus 2; or (5) a decrease in hemoglobin of
≥2 g/dL within 24 hours. Occult bleeding was defined in
the absence of observed blood loss and when either of
the two criteria were met: (1) a decrease in hemoglobin
of ≥2 g/dL within a 24-hour period on CRRT; or (2) fail-
ure of the hemoglobin concentration (in g/dL) to increase
after transfusion by at least the number of units trans-
fused minus 2. During the study, the transfusion threshold
guideline utilized was 7.0 g/dL [15]. Clinically significant
metabolic alkalosis or hypocalcemia was defined as an
adverse event when a threshold of pH >7.50 or serum
ionized calcium of <0.70 mmol/L was met within a con-
secutive 24-hour period.
Statistical analysis
Patient survival proportion and the reasons for
hemofilter termination was compared between groups
using Fisher exact test and the chi-square test. Hemofil-
ter survival times were compared using the Kaplan-
Meier method and the log-rank test [16]. An extension
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of the Cox proportional hazard model that accounted for
the correlation within each individual to clot sequential
hemofilters and adjusted for potential confounding vari-
ables was used to compare the relative hazard of hemofil-
ter failure between treatment groups [17]. Potential
confounding variables included age, gender, and treat-
ment effect as fixed covariates and LOD score, protein
C, and AT-III, as time-dependent covariates. First-order
interaction terms for protein C and AT-III by treatment
assignment were also evaluated. The temporal change in
AT-III levels over time was modeled using random ef-
fects linear regression and adjusting for the effect of anti-
coagulant treatment assignment, age, and gender as fixed
covariates, and LOD score as a time-dependent covari-
ate with interaction terms between treatment and LOD
score [18]. Definite and occult hemorrhage was used
as a composite end point, and comparisons of absolute
rates and relative rates of hemorrhage between treatment
groups were described using a Poisson distribution [19].
Multivariable adjustment for variables including age,
gender, etiology of renal failure, LOD score, protein C,
and AT-III levels was performed using a Poisson regres-
sion model. For the extended Cox proportional hazard
model, the random effects linear regression model, and
the Poisson regression model, backward selection of co-
variates was performed, and covariates were deemed to
be significant in the final model if they obtained a signif-
icance level of P < 0.05.
For the study to have a statistical power of 90% with
a two-sided alpha level of 0.05 to detect an absolute dif-
ference of 10% in hemofilter survival from 1% to 11%
on day 8 after hemofilter initiation, and assuming a rate
of hemofilter censoring of 63%, a total sample size of
96 hemofilters was required [20]. The sample size was
increased to 120 hemofilters to account for previously
observed intrapatient correlation. For the statistical com-
ponent of the interim analysis, the use function of O’Brian
and Fleming was adopted with one interim analysis at the
study midpoint of approximately 30 patients assuming an
average of 2 hemofilters per patient [21]. For analytic pur-
poses, hemofilters were the unit of analysis, and only those
hemofilters consecutively receiving the assigned antico-
agulant were included in the analysis. The analysis was
performed using SAS 8.02 and S-Plus 2000 (Cary, NC,
USA) and conducted according to the intention-to-treat
principle.
RESULTS
Randomization
Recruitment began in April 1999 and ended in June
2002. A total of 285 patients were screened; 33 were
eligible but not randomized (consent refused in 29 and
physician refusal in 4) and 221 patients met exclusion cri-
teria. The remaining 31 patients were randomized into
Table 1. Characteristics of the 30 randomized subjectsa
Citrate Heparin
group group
Characteristic (N = 16) (N = 14)
Male gender No. (%) 7 (43.8) 8 (57.1)
Age years 66.5 ± 14.5 63.9 ± 21.2
Logistic organ dysfunction scoreb 7.75 ± 3.53 9.42 ± 2.31
Etiology of renal failure
Surgical acute tubular necrosis 3 (18.8) 1 (7.1)
No. (%)
Nephrotoxic acute tubular necrosis 3 (18.8) 4 (28.6)
No. (%)
Septic acute tubular necrosis 5 (31.3) 6 (42.9)
No. (%)
Medical acute tubular necrosis 4 (25) 1 (7.1)
No. (%)
Acute glomerulopathies No. (%) 0 (0) 1 (7.1)
Other No. (%) 1 (6.3) 1 (7.1)
Oliguric (<400 mL/24 hours) No. (%) 9 (56.3) 5 (35.7)
Highest urea mmol/Lc 22.8 ± 6.5 22.4 ± 13.1
Highest creatinine lmol/Lc 335 ± 100 297 ± 195
Urine output mLc 986 ± 1347 919 ± 867
Lowest platelet count × 109/Lc 131 ± 38 126 ± 98
Highest INRc 1.4 ± 0.2 1.6 ± 0.8
Protein C lg/mLc 0.65 ± 0.37 0.47 ± 0.29
AT-III lg/mLc 0.78 ± 0.18 0.56 ± 0.21
aPlus-minus values are mean ± SD.
bValues obtained within the first 24 hours after ICU admission.
cValues obtained within the 24 hour period preceding CRRT initiation.
the clinical trial. One patient was excluded after ran-
domization because he had suffered significant abdomi-
nal trauma within three days prior to randomization. The
intention-to-treat analysis was based on 30 patients, 16
randomized to receive heparin and 14 randomized to re-
ceive citrate. All 30 patients were followed to hospital
discharge or death. Two patients crossed over from cit-
rate to heparin, and two patients crossed over from hep-
arin to citrate treatment. The trial stopped early because
of an advantage using citrate anticoagulation. There was
no significant difference between the groups in any of the
baseline characteristics (Table 1). Patient survival to ICU
and hospital discharge was three of 16 patients (19%) in
the citrate group compared to four of 14 patients (29%)
in the heparin group (P = 0.69).
Outcomes
A total of 79 hemofilters were included in the analy-
sis, 43 receiving heparin and 36 receiving citrate. Within
the heparin and citrate groups, 25 (58%) and 12 (33%)
of hemofilters, respectively, clotted or were terminated
because of high hemofilter pressures. The most frequent
reason for hemofilter censoring was for patient transport
in both the citrate (22.2%) and in the heparin groups
(18.6%). The reasons for terminating a hemofilter in the
citrate group were significantly different from those in the
heparin group (P = 0.05; Table 2). The median hemofil-
ter survival time was 124.5 hours (95% CI 95.3 to 157.4)
in the citrate group, which was significantly longer than
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Table 2. Reason for terminating hemofilter by treatment group
Citrate Heparin
Reason for hemofilter termination (N = 36) (N = 43)
Circuit clotting 6 (16.7%) 23 (53.5%)
Switching to intermittent hemodialysis 1 (2.8%) 0
Vascular access malfunction 2 (5.6%) 0
Circuit break/leak 1 (2.8%) 0
Circuit kinking 1 (2.8%) 0
Transport to radiology/operating theatre 8 (22.2%) 8 (18.6%)
High hemofilter pressures 1 (2.8%) 2 (4.7%)
Other reasons 16 (44.4%) 10 (23.3%)
Comparison between groups, chi-square = 12.8764, P = 0.045.
the 38.3 hours (95% CI 24.8 to 61.9) in the heparin group
(P < 0.001) (Fig. 1).
The Cox proportional hazard model included the ef-
fects of treatment, gender, LOD score, and AT-III levels
(Table 3). The relative hazard of hemofilter clotting in
the citrate group was significantly less than in the hep-
arin group (hazard ratio, 0.37; 95% CI 0.20 to 0.70; P =
0.002). Increasing LOD score, male gender, and decreas-
ing AT-III levels were independent predictors of hemofil-
ter failure (Table 3). Neither protein C levels nor the
interaction between AT-III levels and treatment assign-
ment were significant predictors of hemofilter survival.
When considering temporal changes in AT-III levels over
the entire period under study, patients receiving citrate
had a significantly greater rise in their AT-III levels over
time compared to those receiving heparin after adjusting
for illness severity as measured by the LOD score (P =
0.038). Age and gender were not found to be significantly
predictive of temporal changes in AT-III levels during the
period under study.
Adverse events
The duration of time where patients randomized to the
citrate or the heparin group received their assigned anti-
coagulation was 2079 hours and 1444 hours, respectively.
Hemofilters were significantly more often terminated be-
cause of clotting in the heparin (53.5%) compared to the
citrate (16.7%) group, and the resultant “down time” off
renal replacement therapy accounted in large part for the
shorter duration of time on continuous renal replacement
therapy in the heparin group (Table 2). Definite hemor-
rhage did not occur in the citrate group, and occurred in
seven instances in the heparin group. Occult hemorrhage
occurred once in both the citrate and heparin group. Pa-
tients randomized to receive citrate trended toward a re-
duced rate of hemorrhage (relative risk of 0.17; 95% CI
0.03 to 1.04, P = 0.06; Table 4). After adjustment for AT-
III levels and LOD score, the relative risk of hemorrhage
with citrate anticoagulation was significantly lower than
that with heparin (relative risk of 0.14; 95% CI 0.02 to
0.96, P = 0.05; Table 5). In the multivariable model, AT-
III levels trended toward a positive association with the
risk of hemorrhage. Patient age, gender, LOD score, the
etiology of renal failure, and protein C levels were not sig-
nificant predictors of hemorrhage. A total of 15 units and
20 units of red blood cells were transfused, respectively,
in the citrate and heparin groups. The relative risk of red
blood cell transfusion was lower in the citrate group, but
was not statistically significant (relative risk 0.53, 95% CI
0.24 to 1.20; P = 0.13; Table 4). A total of 35 units and
5 units of plasma were transfused, respectively, in the
citrate and heparin groups. The relative risk of plasma
transfusion was also not statistically significant between
citrate and heparin groups (relative risk 4.95, 95% CI 0.47
to 52.30; P = 0.18; Table 4).
Three episodes of metabolic alkalosis occurred in one
patient receiving citrate, and no episodes of alkalosis oc-
curred in any of the patients receiving heparin. Likewise,
two episodes of hypocalcemia occurred in one patient
receiving citrate, and no episodes of hypocalcemia oc-
curred in any of the patients receiving heparin. None of
the episodes of metabolic alkalosis or hypocalcemia were
deemed to be life threatening.
DISCUSSION
Continuous renal replacement therapy is an important
component in the treatment of ARF because it offers bet-
ter hemodynamic tolerance, improved delivered doses of
dialysis, and the ability to provide adequate parenteral
nutrition [7, 22, 23]. For intermittent hemodialysis, prob-
lems with clotting continue to be the most important lim-
its to dialysis adequacy aside from dialysis prescription
[24]. Continuous anticoagulation has remained a major
obstacle to CRRT, and a recent study utilizing either hep-
arin or no anticoagulation in critically ill patients receiv-
ing CRRT demonstrated a median time of three hours per
day where CRRT was not applied because of circuit dis-
ruption. This disruption was correlated with a lower per-
centage reduction in urea and creatinine [25]. Frequent
hemofilter clotting may limit achieving an adequate dial-
ysis dose, and efficient dialysis to specified end points has
been associated with improved mortality in patients with
ARF receiving either intermittent hemodialysis or CRRT
[22, 26].
Our findings are consistent with previous findings
demonstrating the superiority of citrate anticoagulation
compared to unfractionated heparin or low-molecular-
weight heparin with respect to hemofilter thrombus for-
mation seen by electron microscopy [27]. The superiority
of citrate over heparin is also consistent with the only
previously published small randomized trial comparing
the two anticoagulants, with median hemofilter survival
times of 70 hours and 40 hours, respectively, in the citrate
and heparin groups [12]. However, the previous trial did
not adjust for illness severity, gender, and AT-III levels,
Kutsogiannis et al: Citrate versus heparin in CRRT 2365
1.00
Su
rv
iva
l d
ist
rib
ut
io
n 
fu
nc
tio
n
Time to hemofilter failure, hours
0.75
0.50
0.25
0.00
0 25 50 75 100 125 150 175
0137111624
0141020
36
43Hep (N)
Hep (N)
Heparin group
Citrate group
Fig. 1. Kaplan-Meier survival function indi-
cating hemofilter survival times between hep-
arin and citrate treatment groups.
Table 3. Extended Cox proportional hazard model for hemofilter survival
Coefficient Robust Wald P Hazard
Variable (b) Standard error v 2 value ratio 95% CI
Citratea −0.992 0.323 −3.07 0.002 0.371 0.197–0.699
LOD scoreb 0.237 0.055 4.30 < 0.001 1.267 1.138–1.411
Femalec −0.646 0.261 −2.47 0.01 0.524 0.314–0.874
AT-IIId −1.541 0.612 −2.52 0.01 0.214 0.065–0.712
aHeparin as reference.
bLogistic organ dysfunction score.
cMale as reference.
dPer-unit increase in AT-III level.
Table 4. Incidence of definite or occult hemorrhage and transfusion requirements
Citratea,b Heparina,b Relative riskb P value
Definite or occult hemorrhage 0.01 (0–0.04) 0.13 (0.04–0.23) 0.17 (0.03–1.04) 0.06
Red blood cell transfusion U 0.17 (0.10–0.25) 0.33 (0.18–0.49) 0.53 (0.24–1.20) 0.13
Plasma transfusion U 0.40 (0.29–0.52) 0.08 (0.01–0.16) 4.95 (0.47–52.30) 0.18
aIncident rates are defined as the rate of definite or occult hemorrhage per 24-hour period at risk (on CRRT) or units of red blood cells or plasma transfused per
24-hour period at risk (on CRRT).
bThe numbers in brackets indicate the 95% CIs.
all of which significantly influenced hemofilter survival in
this study. In an observational study of regional citrate an-
ticoagulation, median hemofilter survival time was only
24.2 hours, and this may have been attributable to inad-
equate experience with regional citrate anticoagulation
[28]. The median hemofilter survival of 38 hours in our
heparin group is comparable with previously described
median times using unfractionated heparin or no antico-
agulation (15 to 51.7 hours), dalteparin (46.8 hours), and
hirudin (22 hours) [12, 29–32]. Significantly fewer units
of red blood cells (0.17 per day at risk) were transfused
in the citrate group compared to the heparin group (0.33
per day at risk), and both of these rates compare favor-
ably to previously published rates of 1.1 units and 1 unit
per day using unfractionated heparin [12, 33].
Hemofilter clotting is thought to be associated with
low baseline levels of AT–III, heparin cofactor II, and
tissue factor pathway inhibitor, and a rise in thrombin-
antithrombin complexes, implicating thrombin genera-
tion as a major factor [34, 35]. Our finding that AT-III,
in a time-dependent fashion, was a strong predictor of
hemofilter clotting confirms these findings. Acquired AT-
III deficiency has been well described as an etiologic fac-
tor in the microvascular thrombosis of sepsis, as have the
natural anticoagulant and anti-inflammatory properties
of AT-III [36–38]. However, a recent randomized trial
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Table 5. Multivariable Poisson regression model of relative risk of
definite or occult hemorrhage during CRRT
Variable Relative risk Chi-square P value 95% CI
Intercept 0.001 7.10 0.008 0.00001–0.174
Citratea 0.137 4.01 0.05 0.020–0.959
AT-III 6.647 3.03 0.08 0.789–56.003
LOD Scoreb 0.924 0.10 0.75 0.571–1.494
aSystemic heparin anticoagulation as reference.
bLogistic organ dysfunction score.
using AT-III in sepsis failed to demonstrate a mortal-
ity benefit [39]. The generation of clot by artificial mem-
branes depends on the activation of surface factor XII,
which subsequently initiates the clotting cascade, culmi-
nating in the generation of thrombin and fibrin [27]. AT-
III’s ability to inhibit almost all coagulation factors ren-
ders it the most important serpin in the formation of clot,
and this may explain its independent effect on hemofilter
survival compared with the lack of effect of protein C ob-
served in this study [36]. This study also demonstrated a
significantly greater increase in AT-III levels over time in
the citrate group compared to the heparin group after ad-
justment for temporal changes in illness severity. We hy-
pothesize that heparin binding to AT-III may account for
the delayed increase in AT-III levels in those patients an-
ticoagulated with heparin. However, despite these tem-
poral differences in AT-III levels between groups, citrate
anticoagulation remained an independent predictor of
improved hemofilter survival after adjustment for these
temporal differences in AT-III levels.
This study was limited because treatment assignments
were randomized but unblinded. However, every effort
was made to reduce bias with respect to the provision
of CRRT and administration of blood products by using
a transfusion threshold of 7.0 g/dL [15]. Our study was
undertaken within a single geographic region with ex-
tensive familiarity with regional citrate anticoagulation
and may not be generalizable. Other less experienced
centers have noted both hypocalcemia and metabolic al-
kalosis with poorer hemofilter survival when initiating
their program [28]. Every effort was made to monitor the
effects of either heparin or regional citrate anticoagula-
tion in a timely manner at least every four hours, and
this was outlined in protocol form a priori. Despite this,
more frequent anticoagulant monitoring in the form of
INR, PTT, and posthemofilter ionized calcium measure-
ments were permitted, and, if performed unevenly be-
tween treatment groups, may have accounted for some
of the differences demonstrated in hemofilter survival.
Although this study population was not at a high risk
of bleeding, one could assume that the rates of bleeding
would have been proportionately higher with heparin if a
high bleeding risk population were studied. No significant
difference in ICU or hospital mortality was found; how-
ever, the study was not powered to determine differences
in mortality end points.
CONCLUSION
Our findings demonstrate the superiority of regional
citrate anticoagulation over systemic heparin anticoag-
ulation in a population of critically ill patients suffering
from ARF. Given the results of this study, regional citrate
anticoagulation should be advocated as the anticoagu-
lation mode of choice in patients receiving CRRT, who
are at both high risk and non-high risk for hemorrhage.
Moreover, both the degree of illness severity and serum
AT-III levels predict hemofilter survival time, and pro-
vide further insights into the importance of known and
unknown hematologic factors in the pathophysiology of
critical illness.
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